

25th September 2024

- | | |
|---|---|
| <p>(1) BSE Ltd Listing Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg</p> | |

Dear Sir / Madam,

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of the Listing Regulations, we hereby notify that, Cipla (EU) Limited, wholly owned subsidiary of the Company in UK, has entered into a definitive agreement on 25th September 2024 for purchase of entire 6.9124% equity interest of Jiangsu Xidi Pharmaceuticals Co., Ltd. (formerly known as Jiangsu Acebright Pharmaceuticals Co., Ltd.) held in Cipla (Jiangsu) Pharmaceuticals Co., Ltd., China (‘Cipla Jiangsu’), subsidiary.

Upon completion of the transaction, Cipla Jiangsu will become a wholly owned step-down subsidiary of the Company.

In compliance with the provisions of Regulation 30 of the Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July 2023, we are enclosing a disclosure in Annexure – I to this letter.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary
Encl: as above

Prepared by: Mandar Kurghode

Annexure- I

SEBI Circular no. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July 2023

| Sr. No. | Particulars | Details |
|---------|---|---|
| a) | Name of the target entity, details in brief such as size, turnover etc.; | <p>Name of the target entity: Cipla (Jiangsu) Pharmaceuticals Co., Ltd. ('Cipla Jiangsu')</p> <p>Brief details: Cipla Jiangsu was incorporated in China on 8th August 2019 as a joint venture between Cipla (EU) Limited ('Cipla EU') and Jiangsu XiDi Pharmaceuticals Co., Ltd ('Xidi'), for the purpose of manufacturing, selling and distribution of pharmaceutical products, research and development services and analytical development services. Cipla Jiangsu has set-up a manufacturing facility in China, primarily focused on inhalation respules products.</p> <p>Currently, Cipla EU and Xidi holds 93.0876% and 6.9124% equity interest respectively in Cipla Jiangsu.</p> <p>Turnover of last 3 years: Nil</p> |
| b) | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"; | <p>The proposed transaction is a related party transaction and will be on an arm's length basis.</p> <p>None of the promoter/promoter group/group companies have any interest in Cipla Jiangsu.</p> |
| c) | Industry to which the entity being acquired belongs; | Pharmaceutical Industry. |
| d) | Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); | The said transaction is being carried out in terms of the existing joint venture contract between the parties and will provide Cipla EU with full control and ownership of Cipla Jiangsu. |

| | | |
|----|---|---|
| e) | Brief details of any governmental or regulatory approvals required for the acquisition; | The purchase of additional equity interest will be subject to (i) compliance with applicable laws and (ii) approvals from regulatory authorities in China. |
| f) | Indicative time-period for completion of the acquisition; | The transaction is expected to be completed on or before 15 th November 2024 or such other date as maybe mutually agreed between the parties and shall be subject to successful completion/ waiver of conditions as mentioned in such definitive agreements and receipt of regulatory approvals. |
| g) | Nature of consideration - whether cash consideration or share swap and details of the same; | Cash Consideration. |
| h) | Cost of acquisition and/or the price at which the shares are acquired; | RMB 35,849,118. |
| i) | Percentage of shareholding / control acquired and / or number of shares acquired; | Upon purchase of 6.9124% equity interest from Xidi, Cipla Jiangsu will become a wholly owned subsidiary of Cipla EU. |
| j) | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief) | Please refer (a) above. |